A preregistered systematic review of poststroke psychosis examining clinical characteristics, prevalence, diagnostic procedures, lesion location, treatments, risk factors and outcome. Neuropsychiatric outcomes following stroke are common and severely impact quality of life. No previous reviews have focused on poststroke psychosis despite clear clinical need. CINAHL, MEDLINE and PsychINFO were searched for studies on poststroke psychosis published between 1975 and 2016. Reviewers independently selected studies for inclusion, extracted data and rated study quality. Out of 2442 references, 76 met inclusion criteria. Average age for poststroke psychosis was 66.6 years with slightly more males than females affected. Delayed onset was common. Neurological presentation was typical for stroke, but a significant minority had otherwise ‘silent strokes’. The most common psychosis was delusional disorder, followed by schizophrenia-like psychosis and mood disorder with psychotic features. Estimated delusion prevalence was 4.67% (95% CI 2.30% to 7.79%) and hallucinations 5.05% (95% CI 1.84% to 9.65%). Twelve-year incidence was 6.7%. No systematic treatment studies were found. Case studies frequently report symptom remission after antipsychotics, but serious concerns about under-representation of poor outcome remain. Lesions were typically right hemisphere, particularly frontal, temporal and parietal regions, and the right caudate nucleus. In general, poststroke psychosis was associated with poor functional outcomes and high mortality. Poor methodological quality of studies was a significant limitation. Psychosis considerably adds to illness burden of stroke. Delayed onset suggests a window for early intervention. Studies on the safety and efficacy of antipsychotics in this population are urgently needed.

The ongoing opioid epidemic has been a global concern for years, increasingly due to its heavy toll on young people’s lives and prospects. Few studies have investigated trends in use of the wider range of drugs prescribed to alleviate pain, psychological distress and insomnia in children, adolescents and young adults. Our aim was to study dispensation as a proxy for use of prescription analgesics, anxiolytics and hypnotics across age groups (0–29 years) and sex over the last 15 years in a large, representative general population. The study used data from a nationwide prescription database, which included information on all drugs dispensed from any pharmacy in Norway from 2004 through 2019. Age-specific trends revealed that the prevalence of use among children and adolescents up to age 14 was consistently low, with the exception of a substantial increase in use of melatonin from age 5. From age 15–29, adolescents and young adults used more prescription drugs with increasing age at all time points, especially analgesics and drugs with higher potential for misuse. Time trends also revealed that children from age 5 were increasingly dispensed melatonin over time, while adolescents from age 15 were increasingly dispensed analgesics, including opioids, gabapentinoids and paracetamol. In contrast, use of benzodiazepines and z-hypnotics slightly declined in young adults over time. Although trends were similar for both sexes, females used more prescription drugs than their male peers overall. The upsurge in use of prescription analgesics, anxiolytics and hypnotics among young people is alarming.Trial registration The study is part of the overarching Killing Pain project. The rationale behind the Killing Pain research was pre-registered through ClinicalTrials.gov on April 7, 2020. Registration number NCT04336605; https://clinicaltrials.gov/ct2/show/record/NCT04336605.

No abstract

Supplemental Digital Content is Available in the Text.The Stressful Life Events Screening Questionnaire demonstrates satisfactory sensitivity, specificity, temporal stability, and acceptability in a chronic pain clinic and can help guide clinical practice within these settings.

No abstract

Aims and objectives: A pre-registered systematic review of post-stroke psychosis examining clinical characteristics, prevalence, diagnostic procedures, lesion location, treatments, risk factors, and long-term outcomes.Background: Neuropsychiatric outcomes following stroke are common and severely impact quality of life. Previous reviews have focused on anxiety, depression and cognitive impairment in stroke but no systematic review has yet focused on post-stroke psychosis despite clear clinical need.Methods: CINAHL, MEDLINE and PsychINFO were searched for studies on post-stroke psychosis published between 1975 and 2016. Reviewers independently selected studies for inclusion, extracted data, and rated study quality.Results: Out of 2442 references, 75 met the inclusion criteria. Average age for post-stroke psychosis was 60.8 years with slightly more males than females affected. Average psychosis onset was 7.1 months after stroke. Neurological presentation was typical for stroke but a significant minority had ‘silent strokes’. The most common psychosis was delusional disorder, followed by schizophrenia-like psychosis and mood disorder with psychotic features. Mean prevalence was 4.1% (range 0.2% – 9.9%). 12 year incidence was 6.7%. Antipsychotic medication was commonly prescribed and the most frequent outcome was complete remission. Lesions were typically right hemisphere, particularly frontal, temporal and parietal regions, as well as the right caudate nucleus. Post-stroke psychosis was associated with poor functional outcomes and high mortality. Methodological quality of the studies was poor.Conclusion: Psychosis considerably adds to illness burden of stroke. Delayed onset suggests a window for early detection and intervention. Studies on the safety and efficacy of antipsychotics in this population are urgently needed.